Background: In the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions.
Research Design And Methods: We analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.
Results: Among 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.
Conclusions: This highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14787210.2024.2389884 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
PLoS Med
January 2025
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials.
View Article and Find Full Text PDFReal-world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.
Signal Transduct Target Ther
January 2025
Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized patients with COVID-19 from eleven hospitals in Henan and Xinjiang Provinces, China.
View Article and Find Full Text PDFEvaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID) with Concomitant Medications in Real-World Clinical Settings.
Pathogens
November 2024
Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague, Czech Republic.
Background: This research article delves into the battle against the COVID-19 pandemic, focusing on the efficacy and, particularly, the safety of the combination of nirmatrelvir with ritonavir, which is found in the pharmaceutical product Paxlovid. This study aims to analyze the potential interactions of commonly prescribed medicinal products with Paxlovid, shedding light on its utilization in specific medical fields.
Methods: Prescription data from the Czech Republic's Institute of Health Information and Statistics (IHIS CR) was analyzed, covering 4 million COVID-19 patients and 87.
Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
PLoS One
December 2024
The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety. Based on the FDA adverse event reporting system (FAERS) database, this study aims to mine the adverse reaction signals of the latest major recommended drug Nirmatrelvir/Ritonavir for the antiviral treatment of COVID-19, so as to provide a basis for safe and rational drug use.
View Article and Find Full Text PDFReal-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19.
Pulm Ther
December 2024
Eli Lilly and Company, Indianapolis, IN, USA.
Introduction: This real-world study assessed the effectiveness of bebtelovimab (BEB) versus nirmatrelvir/ritonavir (NR) among outpatients with COVID-19 during the Omicron variant era.
Methods: We conducted a cohort study evaluating patients treated with BEB or NR from February to August 2022 (study period). Follow-up began the day after treatment and continued for 30 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!